News

Osmol Therapeutics Announces Closing of Series A-1 Funding to Advance the Clinical Development of the First Therapy to Prevent Chemotherapy-induced Neuropathy

Osmol Therapeutics today announced that it has initiated Investigational New Drug (IND) enabling studies to develop a therapy to prevent chemotherapy-induced peripheral neuropathy (CIPN). A phase 1 clinical study is projected to begin in 2022. There are currently no Food and Drug Administration (FDA) approved therapies for the prevention or treatment of CIPN, a debilitating condition resulting from the off-target toxicity of many chemotherapy treatments.

CEO of Osmol Therapeutics Leads Virtual Charge to Develop Ground-Breaking Treatment for Prevent Chemo Side-Effects

Bob Linke, CEO of Osmol, was interviewed for the CEO Leadership Series sponsored by Ashton-Tweed, a life sciences executive search firm Mr. Linke discusses OSM-0205, the company’s ground-breaking CIPN treatment and managing a virtual team during the COVID-19 pandemic.

Osmol Therapeutics Initiates IND Enabling Studies to Develop First Therapy for Prevention of Chemotherapy-Induced Peripheral Neuropathy

Osmol Therapeutics today announced that it has initiated Investigational New Drug (IND) enabling studies to develop a therapy to prevent chemotherapy-induced peripheral neuropathy (CIPN). A phase 1 clinical study is projected to begin in 2022. There are currently no Food and Drug Administration (FDA) approved therapies for the prevention or treatment of CIPN, a debilitating condition resulting from the off-target toxicity of many chemotherapy treatments.

BioWorld News to Note for May 13, 2021

Osmol Therapeutics Inc., of New Haven, Conn., said it initiated IND-enabling studies to develop a therapy to prevent chemotherapy-induced peripheral neuropathy (CIPN). A phase I study is projected by the company to begin in 2022.